Silo Pharma (NASDAQ:SILO – Get Free Report) and Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk.
Insider & Institutional Ownership
5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 2.2% of Silo Pharma shares are owned by company insiders. Comparatively, 20.5% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Silo Pharma and Palvella Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
| Palvella Therapeutics | 1 | 0 | 13 | 2 | 3.00 |
Earnings & Valuation
This table compares Silo Pharma and Palvella Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silo Pharma | $70,000.00 | 69.32 | -$4.39 million | ($0.95) | -0.38 |
| Palvella Therapeutics | $42.81 million | 38.63 | -$17.43 million | ($2.63) | -53.11 |
Silo Pharma has higher earnings, but lower revenue than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Silo Pharma has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500.
Profitability
This table compares Silo Pharma and Palvella Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silo Pharma | -7,050.00% | -107.03% | -77.06% |
| Palvella Therapeutics | N/A | -64.41% | -42.74% |
Summary
Palvella Therapeutics beats Silo Pharma on 10 of the 15 factors compared between the two stocks.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
About Palvella Therapeutics
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
Receive News & Ratings for Silo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
